Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival…
Regions & Measurement
Explore the main themes, entities and connections around Fotemustine. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
melanoma treatment survival dtic toxicity nitrosourea metastatic dacarbazine alkylating agent used available europe approved united states fda study shown produces
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Fotemustine | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Fotemustine | AHFS/Drugs.com | International Drug Names | 1.00 | infobox |
| Fotemustine | ATC code | L01AD05 (WHO) | 1.00 | infobox |
| Fotemustine | CAS Number | 92118-27-9 N | 1.00 | infobox |
| Fotemustine | ChEMBL | ChEMBL549386 Y | 1.00 | infobox |
| Fotemustine | ChemSpider | 94600 Y | 1.00 | infobox |
| Fotemustine | CompTox Dashboard (EPA) | DTXSID80869091 | 1.00 | infobox |
| Fotemustine | DrugBank | DB04106 N | 1.00 | infobox |
| Fotemustine | ECHA InfoCard | 100.158.792 | 1.00 | infobox |
| Fotemustine | Formula | C9H19ClN3O5P | 1.00 | infobox |
| Fotemustine | KEGG | D07255 Y | 1.00 | infobox |
| Fotemustine | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Fotemustine | Molar mass | 315.69 g·mol−1 | 1.00 | infobox |
| Fotemustine | Pregnancy category | AU: D | 1.00 | infobox |
| Fotemustine | PubChem CID | 104799 | 1.00 | infobox |
| Fotemustine | Trade names | Mustophoran | 1.00 | infobox |
| Fotemustine | UNII | GQ7JL9P5I2 | 1.00 | infobox |
| Fotemustine | is a | nitrosourea alkylating agent used in the treatment of metastatic melanoma | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.